Santarus moves up after Q2 beat, upbeat guidance

|By:, SA News Editor

Shares of Santarus (SNTS) are trading higher by 8.6% premarket after the company handily beat estimates with Q2 results Tuesday evening.

Q2 Y/Y revenue growth by product: Glumetza, 39%; Zegerid, 109%; Cycloset, 115%; Fenoglide, flat.

The company is raising FY13 guidance based on the "robust" quarterly performance.

FY13 outlook: Adjusted EPS of $1.21-1.26 on revenue of $355-360M. Consensus is $0.85/ share on sales of $$345.81M. (PR)